Hostname: page-component-745bb68f8f-f46jp Total loading time: 0 Render date: 2025-02-06T04:36:10.514Z Has data issue: false hasContentIssue false
  • English
  • Français

Propranolol in Schizophrenia

I. Comparison of Propranolol, Chlorpromazine and Placebo

Published online by Cambridge University Press:  29 January 2018

M. Peet ,
M. S. Bethell ,
A. Coates ,
A. K. Khamnee ,
P. Hall ,
S. J. Cooper ,
D. J. King  and
R. A. Yates
M. Peet*
Affiliation:
ICI Ltd, Pharmaceuticals Division, and Clinical Assistant, Parkside Hospital, Macclesfield, Cheshire and St Edward's Hospital, Cheddleton, Leek, Staffordshire
M. S. Bethell
Affiliation:
Parkside Hospital
A. Coates
Affiliation:
Worcester District, Hon. Visiting Research Fellow, University of Aston, Birmingham, Worcester Royal Infirmary, Worcester
A. K. Khamnee
Affiliation:
Worcester District, Hon. Visiting Research Fellow, University of Aston, Birmingham, Worcester Royal Infirmary, Worcester
P. Hall
Affiliation:
Worcester District, Hon. Visiting Research Fellow, University of Aston, Birmingham, Worcester Royal Infirmary, Worcester
S. J. Cooper
Affiliation:
Holywell Hospital, Antrim
D. J. King
Affiliation:
Holywell Hospital, Antrim
R. A. Yates
Affiliation:
Clinical Research Department, ICI Ltd, Pharmaceuticals Division, Alderley Park, Macclesfield, Cheshire
*
∗Presently Consultant Psychiatrist, Walton Hospital, Chesterfield, Derbyshire.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Fifty-three hospitalized chronic schizophrenic patients were treated with either propranolol, chlorpromazine or placebo in a double-blind randomized trial for up to three months. Propranolol in a usual dose of 640 mg/day, produced marked cardiovascular effects but no improvement in schizophrenic symptomatology relative to placebo. The effects of chlorpromazine were small and inconsistent.

Type
Papers
Information
The British Journal of Psychiatry , Volume 139 , Issue 2 , August 1981 , pp. 105 - 111
Copyright
Copyright © Royal College of Psychiatrists, 1981 

Footnotes

∗∗

Reprint requests.

References

Atsmon, A., Blum, I., Steiner, M., Latz, A. & Wijsenbeek, H. (1972) Further studies with propranolol in psychotic patients. Psychopharmacologia, 27, 249–54.CrossRefGoogle ScholarPubMed
Belmaker, R. H., Ebstein, R. P., Dasberg, H., Levy, A., Sedvall, G. & Van Praag, H. M. (1979) The effect of propranolol treatment in schizophrenia on CSF amine metabolites and prolactin. Psychopharmacology, 63, 293–6.CrossRefGoogle ScholarPubMed
Bennett, B. M. (1968) Rank-order tests of linear hypotheses. Journal of the Royal Statistical Society, 30, 483–9.Google Scholar
Bremner, R. M., Greengrass, P. M., Morville, M. & Blackburn, K. J. (1978) Effect of tolamolol and other beta-adrenoceptor blocking drugs on [3H] haloperidol binding to rat striatal membrane preparations. Journal of Pharmacy and Pharmacology, 30, 388–90.Google Scholar
Chouinard, G. & Jones, B. D. (1980) Neurolepticinduced supersensitivity psychosis: clinical and pharmacological characteristics. American Journal of Psychiatry, 137, 16—21.Google Scholar
Crow, T. J. (1980) Molecular pathology of schizophrenia: more than one disease process? British Medical Journal, 280, 66–8.CrossRefGoogle ScholarPubMed
Dunnett, C. W. (1964) New tables for multiple comparisons with a control. Biometrics, 21, 482–91.Google Scholar
Elizur, A., Segal, Z., Yeret, A., Davidson, S. & Atsmon, A. (1979) Antipsychotic effect of propranolol on chronic schizophrenics: study of a gradual treatment regimen. Psychopharmacology, 60, 189–94.Google Scholar
Feighner, J. P., Robins, E., Guze, S. B., Woodruff, R. A., Winokur, G. & Munoz, R. (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 57—63.Google Scholar
Fraser, H. S. & Carr, A. C. (1976) Propranolol psychosis. British Journal of Psychiatry, 129, 508–12.Google Scholar
Gardos, G., Cole, J. O., Volicer, L., Orzack, M. H. & Oliff, A. C. (1973) A dose-response study of propranolol in chronic schizophrenics. Current Therapeutic Research, 15, 314–23.Google Scholar
Gershon, E. S., Goldstein, R. E., Moss, A. J. & Kammen, V., Kammen, D.P. (1979) Psychosis with ordinary doses of propranolol. Annals of Internal Medicine, 90, 938–9.Google Scholar
Guy, W., Petrie, W. & Cleary, P. (1978) The incidence of treatment emergent symptoms under chlorpromazine and placebo conditions. Psychopharmacology Bulletin, 14, 22–4.Google ScholarPubMed
Hanssen, T., Heyden, T., Sundberg, I., Alfredsson, G., Nybäck, H. & Wetterberg, L. (1980) Propranolol in schizophrenia. Archives of General Psychiatry, 37, 685–90.Google Scholar
Honigfeld, G., Gillis, R. D. & Klett, C. J. (1966) NOSIE—30: A treatment-sensitive ward behaviour scale. Psychological Reports, 19, 180–2.Google Scholar
Hughes, J. S. & Little, J. C. (1967) An appraisal of the continuing practice of prescribing tranquillizing drugs for long-stay psychiatric patients. British Journal of Psychiatry, 113, 867–73.Google Scholar
King, D. J., Turkson, S. N. A., Liddle, J. & Kinney, C. D. (1980) Some clinical and metabolic aspects of propranolol in chronic schizophrenia. British Journal of Psychiatry, 137, 458–68.CrossRefGoogle ScholarPubMed
Klawans, H. L., Goetz, C. G. & Perlik, S. (1980) Tardive dyskinesia: review and update. American Journal of Psychiatry, 137, 900–8.Google Scholar
Koehler, K. & Guth, W. (1977) Schizophrenieähnliche Psychose nach Einnahme von Propranolol. Münchener Medizinische Wochenschrift, 119, 443–4.Google Scholar
Letemendia, F. J. J. & Harris, A. D. (1967) Chlorpromazine and the untreated chronic schizophrenic: a long-term trial. British Journal of Psychiatry, 113, 950–8.Google Scholar
Lindstrom, L. H. & Persson, E. (1980) Propranolol in chronic schizophrenia: a controlled study in neuroleptic-treated patients. British Journal of Psychiatry, 137, 126–30.Google Scholar
Marsden, C. D. & Jenner, P. (1980) The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychological Medicine, 10, 55—72.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) The brief psychiatric rating scale. Psychological Reports, 10, 799—812.Google Scholar
Peet, M., Middlemiss, D. N. & Yates, R. A. (1980) Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients. Lancet, ii, 978.Google Scholar
Peet, M., Middlemiss, D. N. & Yates, R. A. (1981) Propranolol in schizophrenia II. Clinical and biochemical aspects of combining propranolol with chlorpromazine. British Journal of Psychiatry (in press).Google Scholar
Rackensperger, W., Gaupp, R., Mattke, D. J., Schwartz, D. & Stutte, K. H. (1974) Behandlung von akuten schizophrenen Psychosen mit Beta-receptoren-blockern. Archiv für Psychiatrie und Nervenkrankheiten, 219, 29—36.Google Scholar
Ridges, A. P., Lawton, K., Harper, P., Ghosh, C. & Hindson, N. (1977) Propranolol in schizophrenia. Lancet, ii, 986.Google Scholar
Sheppard, G. P. (1979) High-dose propranolol in schizophrenia. British Journal of Psychiatry, 134, 470–6.Google Scholar
Stam, F. C. (1971) Enkele ervaringen met propranolol-behandeling van schizophrenen. Nederlandse Tijdschrift voor Psychiatrie, 13, 422–6.Google Scholar
Steinert, J. & Pugh, C. R. (1979) Two patients with schizophrenic-like psychosis after treatment with beta-adrenergic blockers. British Medical Journal, i, 790.Google Scholar
Tobias, L. L. & Macdonald, M. L. (1974) Withdrawal of maintenance drugs with long-term hospitalised mental patients: a critical review. Psychological Bulletin, 81, 107–25.Google Scholar
Tyrer, P. J. (1977) Propranolol in schizophrenia. Lancet, ii, 761.Google Scholar
Whitlock, F. A. & Bonfield, A. R. (1980) Propranolol psychosis. Medical Journal of Australia, 1, 184–5.Google Scholar
Yorkston, N. J., Zaki, S. A., Malik, M. K. U., Morrison, R. C. & Havard, C. W. H. (1974) Propranolol in the control of schizophrenic symptoms. British Medical Journal, iv, 633–5.Google Scholar
Yorkston, N. J., Zaki, S. A., Themen, J. F. A. & Havard, C. W. H. (1976) Propranolol to control schizophrenic symptoms: 55 patients. Advances in Clinical Pharmacology, 12, 91—104.Google Scholar
Yorkston, N. J., Zaki, S. A., Pitcher, D. R., Gruzelier, J. H., Hollander, D. & Sergeant, H. G. S. (1977a) Propranolol as an adjunct to the treatment of schizophrenia: Lancet, ii, 575–8.Google Scholar
Yorkston, N. J., Gruzelier, J. H., Zaki, S. A., Hollander, D., Pitcher, D. R. & Sergeant, H. G. S. (1977b) Propranolol in chronic schizophrenia. Lancet, ii, 1082–3.Google Scholar
Yorkston, N. J., Zaki, S. A., Weller, M. P., Gruzelier, J. H. & Hirsch, S. R. (1981) DL-propranolol and chlorpromazine following admission for schizophrenia. Acta Psychiatrica Scandinavica, 63, 13—27.Google Scholar
von Zerssen, D. (1976) Beta-adrenergic blocking agents in the treatment of psychoses. A report on 17 patients. Advances in Clinical Pharmacology, 12, 105–14.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.